Dizon Don S, Tejada-Berges Trevor, Koelliker Susan, Steinhoff Margaret, Granai Cornelius O
Program in Women's Oncology, Department of Obstetrics & Gynecology, Brown Medical School, Providence, RI 02905, USA.
Gynecol Obstet Invest. 2006;62(4):226-8. doi: 10.1159/000094097. Epub 2006 Jun 23.
Ovarian cancer is the most fatal gynecologic malignancy. Women often present late and though median survival has improved, a majority of women will succumb to their disease. The incidence of ovarian cancer among female-to-male transsexuals is not known. We report only the second case of ovarian cancer in a female-to-male transsexual while on androgen supplementation therapy. Staining of his tumor for androgen receptors showed abundant expression. Androgen supplementation in this population may be associated with an increased risk of both ovarian cancer and of endometrial cancer. Consideration for bilateral salpingo-oophorectomy as part of gender reassignment surgery should be given, especially in this poorly studied group of patients whose overall risk of ovarian cancer remains unknown.
卵巢癌是最致命的妇科恶性肿瘤。女性患者往往就诊时已属晚期，尽管中位生存期有所改善，但大多数女性仍会死于该病。女性向男性变性者中卵巢癌的发病率尚不清楚。我们报告的是第二例女性向男性变性者在接受雄激素补充治疗时患卵巢癌的病例。其肿瘤的雄激素受体染色显示有大量表达。在这一人群中补充雄激素可能与卵巢癌和子宫内膜癌的风险增加有关。应考虑将双侧输卵管卵巢切除术作为性别重置手术的一部分，尤其是在这一研究较少、卵巢癌总体风险仍不明的患者群体中。
